These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 26959746)

  • 41. Co-delivery of microRNA-21 antisense oligonucleotides and gemcitabine using nanomedicine for pancreatic cancer therapy.
    Li Y; Chen Y; Li J; Zhang Z; Huang C; Lian G; Yang K; Chen S; Lin Y; Wang L; Huang K; Zeng L
    Cancer Sci; 2017 Jul; 108(7):1493-1503. PubMed ID: 28444967
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Gemcitabine mono-therapy versus gemcitabine plus targeted therapy in advanced pancreatic cancer: a meta-analysis of randomized phase III trials.
    Ottaiano A; Capozzi M; De Divitiis C; De Stefano A; Botti G; Avallone A; Tafuto S
    Acta Oncol; 2017 Mar; 56(3):377-383. PubMed ID: 28256961
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine by inhibition of the Akt-GSK3β-Snail pathway.
    Namba T; Kodama R; Moritomo S; Hoshino T; Mizushima T
    Cell Death Dis; 2015 Jun; 6(6):e1795. PubMed ID: 26111057
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer.
    Banerjee S; Zhang Y; Ali S; Bhuiyan M; Wang Z; Chiao PJ; Philip PA; Abbruzzese J; Sarkar FH
    Cancer Res; 2005 Oct; 65(19):9064-72. PubMed ID: 16204081
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
    Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
    Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Redox-responsive targeted gelatin nanoparticles for delivery of combination wt-p53 expressing plasmid DNA and gemcitabine in the treatment of pancreatic cancer.
    Xu J; Singh A; Amiji MM
    BMC Cancer; 2014 Feb; 14():75. PubMed ID: 24507760
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Experimental study of the function and mechanism combining dihydroartemisinin and gemcitabine in treating pancreatic cancer].
    Wang SJ; Sun B; Pan SH; Chen H; Kong R; Li J; Xue DB; Bai XW; Jiang HC
    Zhonghua Wai Ke Za Zhi; 2010 Apr; 48(7):530-4. PubMed ID: 20646665
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Chemoresistance Transmission via Exosome-Mediated EphA2 Transfer in Pancreatic Cancer.
    Fan J; Wei Q; Koay EJ; Liu Y; Ning B; Bernard PW; Zhang N; Han H; Katz MH; Zhao Z; Hu Y
    Theranostics; 2018; 8(21):5986-5994. PubMed ID: 30613276
    [No Abstract]   [Full Text] [Related]  

  • 49. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
    Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
    Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
    Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
    Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sonoporation-enhanced chemotherapy significantly reduces primary tumour burden in an orthotopic pancreatic cancer xenograft.
    Kotopoulis S; Delalande A; Popa M; Mamaeva V; Dimcevski G; Gilja OH; Postema M; Gjertsen BT; McCormack E
    Mol Imaging Biol; 2014 Feb; 16(1):53-62. PubMed ID: 23877869
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Interferon-beta enhances sensitivity to gemcitabine in pancreatic cancer.
    Blaauboer A; Booy S; van Koetsveld PM; Karels B; Dogan F; van Zwienen S; van Eijck CHJ; Hofland LJ
    BMC Cancer; 2020 Sep; 20(1):913. PubMed ID: 32967656
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Targeted delivery of a peripheral benzodiazepine receptor ligand-gemcitabine conjugate to brain tumors in a xenograft model.
    Guo P; Ma J; Li S; Guo Z; Adams AL; Gallo JM
    Cancer Chemother Pharmacol; 2001 Aug; 48(2):169-76. PubMed ID: 11561783
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fasting cycles potentiate the efficacy of gemcitabine treatment in in vitro and in vivo pancreatic cancer models.
    D'Aronzo M; Vinciguerra M; Mazza T; Panebianco C; Saracino C; Pereira SP; Graziano P; Pazienza V
    Oncotarget; 2015 Jul; 6(21):18545-57. PubMed ID: 26176887
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells.
    Thoennissen NH; Iwanski GB; Doan NB; Okamoto R; Lin P; Abbassi S; Song JH; Yin D; Toh M; Xie WD; Said JW; Koeffler HP
    Cancer Res; 2009 Jul; 69(14):5876-84. PubMed ID: 19605406
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.
    Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K
    Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clobenpropit enhances anti-tumor effect of gemcitabine in pancreatic cancer.
    Paik WH; Ryu JK; Jeong KS; Park JM; Song BJ; Lee SH; Kim YT; Yoon YB
    World J Gastroenterol; 2014 Jul; 20(26):8545-57. PubMed ID: 25024609
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Induction of Metastasis by Low-dose Gemcitabine in a Pancreatic Cancer Orthotopic Mouse Model: An Opposite Effect of Chemotherapy.
    Sugisawa N; Miyake K; Higuchi T; Oshiro H; Zhang Z; Park JH; Kawaguchi K; Chawla SP; Bouvet M; Singh SR; Unno M; Hoffman RM
    Anticancer Res; 2019 Oct; 39(10):5339-5344. PubMed ID: 31570427
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Interleukin-4 cytotoxin therapy synergizes with gemcitabine in a mouse model of pancreatic ductal adenocarcinoma.
    Shimamura T; Royal RE; Kioi M; Nakajima A; Husain SR; Puri RK
    Cancer Res; 2007 Oct; 67(20):9903-12. PubMed ID: 17942922
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy.
    Camp ER; Wang C; Little EC; Watson PM; Pirollo KF; Rait A; Cole DJ; Chang EH; Watson DK
    Cancer Gene Ther; 2013 Apr; 20(4):222-8. PubMed ID: 23470564
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.